No Picture
Trading Ideas

Two Ways to Resolve the Opioid Crisis

I always thought that the Vietnam War would be the worst mass killer of Americans I’d see in my lifetime. More than 58,000 American soldiers died.
But the opioid epidemic’s appalling toll amounts to nearly seven Vietnam Wars.
Opioid addiction is a national tragedy. Opioids have caused more than 400,000 deaths in America alone. And when counting the friends, family and loved ones of those victims, millions more have suffered.
It’s also a deeply personal tragedy shared by millions of Americans. I’ve written about addiction in my own family.
Enough is enough. I’m for anything that fights or reduces opioid addiction. And I mean …read more […]

No Picture
Trading Ideas

Microsoft’s Head of AI and Research to Leave the Company

(Bloomberg) — Microsoft Corp. said Harry Shum, who oversees research and artificial intelligence at the world’s largest software maker, will leave the company in February. Chief Technology Officer Kevin Scott will take over Shum’s duties effective immediately.Shum, a 23-year Microsoft veteran with a doctorate in robotics, was one of the founding members of Microsoft’s research lab in Beijing and also ran Bing search engine product development. He plans to depart Feb. 1, and then will be an adviser to Chief Executive Officer Satya Nadella and co-founder Bill Gates, Microsoft said Wednesday in a statement.“Harry has had a profound impact on …read more […]

No Picture
Business News

Trade talks between U.S. and China ‘hit a snag’ over farm purchases: WSJ

U.S.-China trade negotiations have ‘hit a snag’ over farm purchases, with China not wanting a deal that looks one-sided in the favor of the United States, the Wall Street Journal reported https://on.wsj.com/2CEYDR7 on Wednesday, citing people familiar with the matter.

…read more […]

Healthcare

CytoDyn (OTC: CYDY) Receives IRB Approval To Proceed With Compassionate Use Of Leronlimab For Patients With Triple-Negative Breast Cancer

VANCOUVER, Washington, Nov. 12, 2019 – CytoDyn Inc. (otc.qb:CYDY), (“CytoDyn” or the “Company”), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced today it has […]

No Picture
Trading Ideas

Despite Headwinds, Aurora Cannabis (ACB) Stock Is Still a Solid Long-Term Investment

With Aurora Cannabis (ACB) ready to report first quarter results after the closing bell on Thursday, November 14th, the question arises as to whether or not the company will show signs of strength in the near term, or it’ll report numbers that aren’t inspiring at this season of time in its progress.In this article we’ll look at why investors and/or shareholders need to temper their expectations for Aurora in the near term, and why the long-term outlook remains strong.Near-Term OutlookIn the short term I don’t see any significant positive catalysts that will drive the share price of the company up. …read more […]

No Picture
Trading Ideas

CME Plans to Start Brazilian Soybean Futures With B3 Exchange

(Bloomberg) — CME Group Inc. plans to start Brazilian soybean futures with the country’s B3 exchange, giving traders a new hedging tool as the U.S.-China trade war disrupts the global flow of beans, people familiar with the matter said.The contract for soybeans loaded at the port of Santos, Brazil’s biggest, would be cash-settled, according to the people, who asked not to be identified because the plan hasn’t been announced. Futures will be based on assessments by a price-reporting agency, most likely S&P Global Platts, the people said.Brazil has become a powerhouse in soybeans and overtook the U.S. as the top …read more […]

Healthcare

First Patient in CytoDyn’s (OTC: CYDY) Triple-Negative Metastatic Breast Cancer Trial Shows Significant Reduction in Circulating Tumor Cells (CTC) and Reduced Tumor Size

Breakthrough Therapy designation filing possible if more patients show similar positive results VANCOUVER, Washington, Nov. 11, 2019  — CytoDyn Inc. (otc.qb:CYDY), (“CytoDyn” or the “Company”), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 […]